- Human intranasal research has been published in neurologic settings.
- FDA identifies immunogenicity concerns related to aggregation and peptide-related impurities.
- Semax-related bulk substances were reviewed at the July 2026 PCAC meeting.
RESEARCH REBEL • EVIDENCE DOSSIER
Semax
HUMAN RESEARCH OUTSIDE U.S. • FDA SAFETY REVIEWSynthetic ACTH(4–7)-related peptide with published human research, much of it outside the U.S. Evidence is indication-, formulation- and jurisdiction-specific.
- Generalizability to community nootropic use.
- Safety and performance of independently compounded formulations/devices.
PUBLISHED PROTOCOL EVIDENCE
Study parameter ≠ universal protocol.
Published intranasal study parameters are cataloged as study-specific; community cognitive-enhancement amounts are not treated as clinical protocols.
Numerical study entries carry:PopulationRouteFormulationAmountFrequencyDurationEndpointSource
COMMUNITY EVIDENCE
Document it. Don't upgrade it.
Community reports commonly describe focus, fatigue and cognitive effects; adverse effects and product identity belong beside them.
Reported amount/rangeRouteFrequencyDurationGoalReported positivesReported negativesConcurrent compoundsSource + N
COMMUNITY-REPORTED • NOT CLINICALLY VALIDATED